Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. [electronic resource]
Producer: 20041221Description: 240-53 p. digitalISSN:- 1524-9557
- Aged
- CD4 Antigens -- biosynthesis
- CD8 Antigens -- biosynthesis
- Cancer Vaccines -- therapeutic use
- Cell Separation
- Clinical Trials as Topic
- Dose-Response Relationship, Drug
- Flow Cytometry
- Genetic Therapy -- methods
- Genetic Vectors
- Humans
- Immunotherapy
- Interleukin-2 -- genetics
- Male
- Middle Aged
- Mucin-1 -- genetics
- Phenotype
- Prostatic Neoplasms -- therapy
- Reverse Transcriptase Polymerase Chain Reaction
- Th1 Cells
- Time Factors
- Tumor Necrosis Factor-alpha -- metabolism
- Up-Regulation
- Vaccinia virus -- genetics
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.